Egfr-Mutated Lung Cancer, Passaro (Ieo): "With Osimertinib Important Results at 8 Years"
10 Articles
10 Articles
Rome, 21 Sep. (Adnkronos Salute) - 8 years after the use of osimertinib patients improve disease control and survival regardless of the discontinuation of treatment. This is something significant and important for patients with non-small cell lung cancer (Nsclc) with Egfr mutation, a disease that affects around 15% of patients with Nsclc. It is an important step: it confirms that this strategy continues to give benefits that we will clearly try …
(Adnkronos) - 8 years after the use of osimertinib, patients improve disease control and survival regardless of discontinuation of treatment. This is something significant and important for patients with non-small cell lung cancer (Nsclc) with Egfr mutation, a disease that affects around 15% worldwide [...]
Rec News | Lontani dal mainstream
notizie.it(Adnkronos) 8 years after the use of osimertinib, patients improve disease control and survival regardless of the discontinuation of treatment. This is something significant and important for patients with non-small cell lung cancer (Nsclc) with Egfr mutation, a disease that affects around 15% worldwide [...] The article Egfr-mutated lung cancer, Passaro (Ieo):
newsbiella.it
Quotidiano Nazionale(Adnkronos) - "Thanks to precision medicine we are able today to create a gene profiling and molecule of the lung tumor not to small cells and this has allowed in early stage, to change the treatment...
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
